A comparison of measures used to describe adherence to glaucoma medication in a randomised controlled trial

Abstract

Background:

Understanding the magnitude of non-adherence in pre-marketing clinical trials and clinical practice is essential. However, accurately measuring non-adherence to medication is problematic, and the variety of adherence measures and/or calculation methods has led to highly variable results.

Purpose:

To compare commonly used methods for measuring adherence to eye drop therapy in order to assess which methods achieve the most complete datasets over an 8-month monitoring period, to quantify the magnitude of variance in adherence estimations and to review the different methods used to calculate or interpret adherence data.

Methods:

Adherence was measured electronically for 8 months by participants administering eye drops using a Travalert^® dosing aid. The mean number of Travalert dosing aid recorded doses administered over the monitoring period was used to calculate a percentage adherence score. In addition, the value of graphically presenting Travalert dosing aid data to classify patterns of adherence behaviour was explored. The validated Morisky Measure of Adherence Scale and questions requesting participants to report the Frequency of Missed Doses were two measures of self-reported adherence calculated for each participant. Finally, medication possession ratio was calculated from expected repeat prescription orders compared with actual repeat prescription orders.

Results:

For the 208 recruited participants, self-reported adherence was the most reliable method of collecting complete datasets over the 8-month period; 16% of self-reported adherence data were missing compared with 45% of Travalert dosing aid data missing at 8 months. The mean adherence measured over the monitoring period by the Travalert dosing aid was 77%. When adherence measures were dichotomised into adherent and non-adherent groups, the Travalert dosing aid found 54% of participants were adherent, compared to 60% Morisky Measure of Adherence Scale and 57% Frequency of Missed Dose self-report measures. However, there was poor agreement between the Travalert dosing aid measured adherence and self-report measures. Medication possession ratio was not a reliable measure of persistence with medication. Graphical Travalert dosing aid data presentation provided additional information about participant behaviour by indicating that most non-adherence was due to participants taking drug holidays rather than missing occasional doses.

Conclusion:

The analysis provided evidence about the inconsistencies between different monitoring strategies and adherence measures. Furthermore, the analysis highlighted the difficulties in collecting complete data for studies investigating chronic, slowly progressive conditions that require long-term follow-up. Future adherence studies could use multiple methods for quantifying and classifying adherence in parallel, both to maximise precision of adherence estimates and to facilitate comparison between studies. However, the authors are cautious of the effect of using multiple adherence measures on participant behaviour and their potential reactivity effects is an area for future research.

Keywords

Adherence glaucoma methodology study reactivity medication possession ratio self-report electronic monitoring

Get full access to this article

View all access options for this article.

References

Burke

Dunbar-Jacob

Hill

. Compliance with cardiovascular disease prevention strategies: a review of the research. Ann Behav Med 1997; 19: 239–263.

Waterman

Evans

Gray

. Interventions for improving adherence to ocular hypotensive therapy. Cochrane Database Syst Rev 2013; 4: CD006132.

DiMatteo

. Variations in patients’ adherence to medical recommendations: a quantitative review of 50 years of research. Med Care 2004; 42: 200–209.

Kass

Meltzer

Gordon

. Compliance with topical pilocarpine treatment. Am J Ophthalmol 1986; 101: 515–523.

Choo

Rand

Inui

. Validation of patient reports, automated pharmacy records, and pill counts with electronic monitoring of adherence to antihypertensive therapy. Med Care 1999; 37: 846–857.

Kass

Gordon

Meltzer

. Can ophthalmologists correctly identify patients defaulting from pilocarpine therapy? Am J Ophthalmol 1986; 101: 524–530.

Friedman

Hahn

Gelb

. Doctor-patient communication, health-related beliefs, and adherence in glaucoma results from the Glaucoma Adherence and Persistency Study. Ophthalmology 2008; 115: 1320–1327.

Gilbert

Evans

Haynes

. Predicting compliance with a regimen of digoxin therapy in family practice. Can Med Assoc J 1980; 123: 119–122.

Gray

Orton

Henson

. Interventions for improving adherence to ocular hypotensive therapy. Cochrane Database Syst Rev 2009; 2: CD006132.

10.

Litcher-Kelly

Kellerman

Hanauer

. Feasibility and utility of an electronic diary to assess self-report symptoms in patients with inflammatory bowel disease. Ann Behav Med 2007; 33: 207–212.

11.

Diaz

Levine

Sullivan

. Use of the Medication Event Monitoring System to estimate medication compliance in patients with schizophrenia. J Psychiatry Neurosci 2001; 26: 325–329.

12.

Cook

Schmiege

McClean

. Practical and analytic issues in the electronic assessment of adherence. West J Nurs Res 2012; 34: 598–620.

13.

Richardson

Brunton

Olleveant

. A study to assess the feasibility of undertaking a randomized controlled trial of adherence with eye drops in glaucoma patients. Patient Prefer Adherence 2013; 7: 1025–1039.

14.

Ajit

Fenerty

Henson

. Patterns and rate of adherence to glaucoma therapy using an electronic dosing aid. Eye 2010; 24: 1338–1343.

15.

Cate

Bhattacharya

Clark

. Patterns of adherence behaviour for patients with glaucoma. Eye 2013; 27: 545–553.

16.

Blaschke

Osterberg

Vrijens

. Adherence to medications: insights arising from studies on the unreliable link between prescribed and actual drug dosing histories. Annu Rev Pharmacol Toxicol 2012; 52: 275–301.

17.

Sackett

Snow

. Magnitude and measurement of compliance. In: Haynes

Wayne Taylor

Sacket

(eds) Compliance in healthcare. Baltimore, MD; London: The Johns Hopkins University Press, 1979, pp. 11–22.

18.

Olthoff

Schouten

van de Borne

. Noncompliance with ocular hypotensive treatment in patients with glaucoma or ocular hypertension: an evidence-based review. Ophthalmology 2005; 112: 953–961.

19.

Sorensen

Stokes

Purdie

. Medication management at home: medication-related risk factors associated with poor health outcomes. Age Ageing 2005; 34: 626–632.

20.

Leske

Heijl

Hussein

. Factors for glaucoma progression and the effect of treatment: the Early Manifest Glaucoma Trial. Arch Ophthalmol 2003; 121: 48–56.

21.

Heijl

Leske

Bengtsson

. Reduction of intraocular pressure and glaucoma progression: results from the Early Manifest Glaucoma Trial. Arch Ophthalmol 2002; 120: 1268–1279.

22.

Cate

Bhattacharya

Clark

. Protocol for a randomised controlled trial to estimate the effects and costs of a patient centred educational intervention in glaucoma management. BMC Ophthalmol 2012; 12: 57.

23.

Cate

A pilot study to assess the feasibility of using the Travalert dosing aid to measure adherence [master's thesis]. Norwich, UK: University of East Anglia, 2011, p. 127.

24.

Morisky

Green

Levine

. Concurrent and predictive validity of a self-reported measure of medication adherence. Med Care 1986; 24: 67–74.

25.

Friedman

Quigley

Gelb

. Using pharmacy claims data to study adherence to glaucoma medications: methodology and findings of the Glaucoma Adherence and Persistency Study (GAPS). Invest Ophthalmol Vis Sci 2007; 48: 5052–5057.

26.

Fiscella

Green

Patuszynski

. Medical therapy cost considerations for glaucoma. Am J Ophthalmol 2003; 136: 18–25.

27.

Cate

Bhattacharya

Clark

. Improving adherence to glaucoma medication: a randomised controlled trial of a patient-centred intervention (The Norwich Adherence Glaucoma Study). BMC Ophthalmol 2014; 14: 32.

28.

Landis

Koch

. The measurement of observer agreement for categorical data. Biometrics 1977; 33: 159–174.

29.

Gray

Fenerty

Harper

. Individualised patient care as an adjunct to standard care for promoting adherence to ocular hypotensive therapy: an exploratory randomised controlled trial. Eye 2012; 26: 407–417.

30.

McCowan

Wang

Thompson

. The value of high adherence to tamoxifen in women with breast cancer: a community-based cohort study. Br J Cancer 2013; 109: 1172–1180.

31.

Flynn

MacDonald

Murray

. Persistence, adherence and outcomes with antiplatelet regimens following cerebral infarction in the Tayside Stroke Cohort. Cerebrovasc Dis 2012; 33: 190–197.

32.

Taylor

Chen

Smith

. Adherence to inhaled corticosteroids by asthmatic patients: measurement and modelling. Int J Clin Pharm 2014; 36: 112–119.

33.

Langley

Bush

. The Aston Medication Adherence Study: mapping the adherence patterns of an inner-city population. Int J Clin Pharm 2014; 36: 202–211.

34.

Okeke

Quigley

Jampel

. Adherence with topical glaucoma medication monitored electronically: the Travatan Dosing Aid Study. Ophthalmology 2009; 116: 191–199.

35.

Friedman

Jampel

Congdon

. The TRAVATAN Dosing Aid accurately records when drops are taken. Am J Ophthalmol 2007; 143: 699–701.

36.

Lacey

Cate

Broadway

. Barriers to adherence with glaucoma medications: a qualitative research study. Eye 2009; 23: 924–932.

37.

Gadkari

McHorney

. Unintentional non-adherence to chronic prescription medications: how unintentional is it really? BMC Health Serv Res 2012; 12: 98.

38.

Mankarious

Kothe

. A meta-analysis of the effects of measuring theory of planned behaviour constructs on behaviour within prospective studies. Health Psychol Rev. Epub ahead of print 7 July 2014. DOI: 10.1080/17437199.2014.927722.